fbpx

Bausch + Lomb Announces Results from First Phase 3 Trial of NOV03

Bausch + Lomb and Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced statistically significant topline data from the first Phase 3 trial (GOBI trial) evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD).

The GOBI trial met both of its co-primary endpoints, including:

  • Change from baseline in total Corneal Fluorescein Staining (tCFS), a measure of assessing damage to the eye, achieved statistical significance at day 15 (secondary endpoint), with continued results through day 57 (primary endpoint) compared to control;
  • Change from baseline in dryness score achieved statistical significance at day 15 (secondary endpoint), with continued results through day 57 (primary endpoint) compared to control, as rated on a visual analogue scale (VAS) ranging from 0-100 (0 = no discomfort; 100 = maximum discomfort).

The GOBI trial also met all of its secondary endpoints, showing statistically significant improvements in both the signs and symptoms of DED associated with MGD that were studied.

“There is currently no pharmaceutical therapy available in the United States for the treatment of dry eye disease associated with meibomian gland dysfunction,” said Yolande Barnard, vice president and general manager, U.S. Pharmaceuticals, Bausch + Lomb. “These outstanding topline results are very encouraging that we may be able to bring this first-in-class treatment option to market for the millions of patients who have dry eye disease associated with meibomian gland dysfunction.”

“I am very impressed by the positive results from this first Phase 3 study of NOV03, in particular the findings at day 15 in treating the signs and symptoms of the disease,” said Joseph Tauber, M.D., founder of Tauber Eye Center in Kansas City, Mo., and trial investigator. “These findings validate the importance of the continued development of NOV03, and I look forward to seeing additional results from the Phase 3 program.”

The Phase 3 program for NOV03 includes an ongoing second Phase 3, multi-center, randomized, double-masked, saline-controlled trial (MOJAVE study) and a multi-center, open-label, single-arm 12-month safety extension trial (KALAHARI study). Topline results from MOJAVE, if positive, will allow for a filing to the U.S Food and Drug Administration in 2022.

Click HERE for the full press release.

Related:
Bausch Advances Novel Dry Eye Therapeutic to Phase 3

Featured Posts

Perfect Optical Reebok logos

Perfect Optical Partners with Mondottica Group for Exclusive Reebok Eyewear Distribution in Canada

Perfect Optical announces a new partnership with Mondottica Group, marking a significant step in bringing innovative eyewear solutions to the Canadian market.

Learn More
Blackfin G7 Italia 2024

G7: Blackfin Symbol of Italian Excellence

In conjunction with the G7 Summit, currently being held in Borgo Egnazia in Puglia, Italy not only welcomes the heads of state and government but also showcases authentic Made in Italy products through exclusive gifts for the distinguished guests.

Read more
GIGI Studios Anastasia

GIGI STUDIOS Launches the XS Collection for Petite Faces

Anastasia features a geometrical model in a hexagonal shape made in crystal acetate for the front, Havana temples and a laminated endpiece.

Read more

Local Leaders Break Ground on the Waterloo Eye Institute

Former Governor General of Canada David Johnston reflects on the institute’s importance to the community at a ceremony with regional stakeholders and champions.

Read more
MIDO logo

For the Second Year, MIDO Takes First Prize in the MEDIASTARS Press Section with “SPHERES” Communication Campaign

The campaign, developed by Max Galli in partnership with Mixer Group, was the first in the trade show industry to be created with Artificial Intelligence.

Read more
Perfect Optical Reebok logos

Perfect Optical Partners with Mondottica Group for Exclusive Reebok Eyewear Distribution in Canada

Perfect Optical announces a new partnership with Mondottica Group, marking a significant step in bringing innovative eyewear solutions to the Canadian market.

Learn More
Blackfin G7 Italia 2024

G7: Blackfin Symbol of Italian Excellence

In conjunction with the G7 Summit, currently being held in Borgo Egnazia in Puglia, Italy not only welcomes the heads of state and government but also showcases authentic Made in Italy products through exclusive gifts for the distinguished guests.

Read More
GIGI Studios Anastasia

GIGI STUDIOS Launches the XS Collection for Petite Faces

Anastasia features a geometrical model in a hexagonal shape made in crystal acetate for the front, Havana temples and a laminated endpiece.

Read More

Local Leaders Break Ground on the Waterloo Eye Institute

Former Governor General of Canada David Johnston reflects on the institute’s importance to the community at a ceremony with regional stakeholders and champions.

Read More
MIDO logo

For the Second Year, MIDO Takes First Prize in the MEDIASTARS Press Section with “SPHERES” Communication Campaign

The campaign, developed by Max Galli in partnership with Mixer Group, was the first in the trade show industry to be created with Artificial Intelligence.

Read More
Perfect Optical Reebok logos

Perfect Optical Partners with Mondottica Group for Exclusive Reebok Eyewear Distribution in Canada

Perfect Optical announces a new partnership with Mondottica Group, marking a significant step in bringing innovative eyewear solutions to the Canadian market.

Learn More
Blackfin G7 Italia 2024

G7: Blackfin Symbol of Italian Excellence

In conjunction with the G7 Summit, currently being held in Borgo Egnazia in Puglia, Italy not only welcomes the heads of state and government but also showcases authentic Made in Italy products through exclusive gifts for the distinguished guests.

Read more
GIGI Studios Anastasia

GIGI STUDIOS Launches the XS Collection for Petite Faces

Anastasia features a geometrical model in a hexagonal shape made in crystal acetate for the front, Havana temples and a laminated endpiece.

Read more

Local Leaders Break Ground on the Waterloo Eye Institute

Former Governor General of Canada David Johnston reflects on the institute’s importance to the community at a ceremony with regional stakeholders and champions.

Read more
MIDO logo

For the Second Year, MIDO Takes First Prize in the MEDIASTARS Press Section with “SPHERES” Communication Campaign

The campaign, developed by Max Galli in partnership with Mixer Group, was the first in the trade show industry to be created with Artificial Intelligence.

Read more
Perfect Optical Reebok logos

Perfect Optical Partners with Mondottica Group for Exclusive Reebok Eyewear Distribution in Canada

Perfect Optical announces a new partnership with Mondottica Group, marking a significant step in bringing innovative eyewear solutions to the Canadian market.

Learn More
Blackfin G7 Italia 2024

G7: Blackfin Symbol of Italian Excellence

In conjunction with the G7 Summit, currently being held in Borgo Egnazia in Puglia, Italy not only welcomes the heads of state and government but also showcases authentic Made in Italy products through exclusive gifts for the distinguished guests.

Read more
GIGI Studios Anastasia

GIGI STUDIOS Launches the XS Collection for Petite Faces

Anastasia features a geometrical model in a hexagonal shape made in crystal acetate for the front, Havana temples and a laminated endpiece.

Read more

Local Leaders Break Ground on the Waterloo Eye Institute

Former Governor General of Canada David Johnston reflects on the institute’s importance to the community at a ceremony with regional stakeholders and champions.

Read more
MIDO logo

For the Second Year, MIDO Takes First Prize in the MEDIASTARS Press Section with “SPHERES” Communication Campaign

The campaign, developed by Max Galli in partnership with Mixer Group, was the first in the trade show industry to be created with Artificial Intelligence.

Read more